Well differentiated thyroid cancers (WDTC), including papillary (80%) and follicular (10%) types, are the most common endocrine cancers globally. Over the last few decades most the diagnosed cases have fallen into low risk categories. Radioactive iodine-131 (RAI) has an established role in reducing recurrence and improving the survival in high risk patients. In patients with primary tumor size <1 >cm, RAI is not recommended by many thyroid societies. However, low risk WDTC has been an arena of major controversies, most importantly the role and dose of adjuvant RAI for remnant ablation to minimize chances of recurrence and improving survival. This review is an attempt to update readers about the previous and existing practice based on results of non- randomized trials and evolving trends fueled by recently published randomized studies.
Asian Pacific Journal of Cancer Prevention
Zaman, M. U.,
Padhy, A. K.,
(2013). Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus?. Asian Pacific Journal of Cancer Prevention, 14(11), 6209-6213.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol/170
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License